Biotech Bay
Filter News
Found 73,129 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Cortexyme said it plans to provide additional updates pending further talks with the FDA.
-
The FDA placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected adverse events.
-
The company's focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.
-
The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.
-
Money on the Move: January 19 – 25
1/26/2022
Temps are falling and so is investor cash. Here's which biotech companies are scooping up the dollars this week. -
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
1/26/2022
Aligos Therapeutics, Inc. today announced that he first chronic hepatitis B (CHB) patient has been dosed in the multiple ascending dose (MAD) portion of Study ALG-020572-401 (NCT05001022) which is evaluating antisense oligonucleotide (ASO) ALG-020572.
-
Galvani Bioelectronics Announces World’s First Investigational Treatment of Rheumatoid Arthritis Using Splenic Nerve Stimulation
1/26/2022
Galvani Bioelectronics, today announced that the first patient with Rheumatoid Arthritis (RA) has been treated through stimulation of the splenic nerve using its novel bioelectronics platform.
-
BioEclipse Therapeutics Appoints New Board Member and Names Interim CFO
1/26/2022
BioEclipse Therapeutics announced today the appointment of Mahmoud Mahmoudian, Ph.D., FRSC, to the BioEclipse Board of Directors.
-
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
1/26/2022
Kriya Therapeutics, Inc. today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
-
Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin
1/26/2022
Concentric Analgesics, Inc. today announced the closing of a $20 million convertible note financing from a combination of new and existing investors.
-
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
1/26/2022
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application.
-
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
1/26/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB).
-
Subtle Medical Awarded Federal SBIR Grant for Safer Fluoroscopy Exams
1/26/2022
Subtle's AI Aims to Achieve a 6x Reduction in Radiation Dose of Fluoroscopy Exams.
-
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
1/26/2022
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp.
-
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
1/26/2022
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures.
-
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022
1/26/2022
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 after market close on Wednesday, February 16, 2022.
-
Ancora Heart Announces Key Activities at Inaugural Technology and Heart Failure Therapeutics Conference
1/26/2022
Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure, today announced its activities at the upcoming, first ever Technology and Heart Failure Therapeutics conference (THT 2022), which is produced by the Cardiovascular Research Foundation (CRF) and will be held February 1-2 at the New York Marriott Marquis.
-
Carta Healthcare Announces Distinction as an NCDR Certified Software Vendor for the American College of Cardiology’s (ACC) AFib Ablation Registry
1/26/2022
Carta Healthcare, provider of solutions for common healthcare data challenges through a combination of people, processes, and artificial intelligence (AI)–powered technology, today announced that it is now a National Cardiovascular Data Registry (NCDR®) certified software vendor for the American College of Cardiology’s (ACC) AFib Ablation Registry™.
-
Mainz Biomed Announces Pricing of Follow-on Offering
1/26/2022
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,500,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”), for gross proceeds of $22,500,000.